60 Views | 32 Downloads
Anca Pantea Stoian, Email: ancastoian@yahoo.com
Djordje S. Popovic has analysed the literature and wrote the manuscript; Nikolaos Papanas has analysed the literature and wrote the manuscript; Anca Pantea Stoian has analysed the literature, reviewed and edited the manuscript; Ali A. Rizvi has reviewed and edited the manuscript; Andrej Janez has reviewed and edited the manuscript; Manfredi Rizzo did the conceptualisation of the study and also reviewed, edited and finalised the manuscript.
This manuscript was written independently and the authors did not receive financial or professional help for its preparation. Djordje S. Popovic declares associations that might represent a conflict of interest with the following companies: Abbott, Alkaloid, AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, and Worwag Pharma. Nikolaos Papanas has been an advisory board member of TrigoCare International, Abbott, AstraZeneca, Elpen, MSD, Novartis, Novo Nordisk, Sanofi-Aventis, and Takeda; has participated in sponsored studies by Eli Lilly, MSD, Novo Nordisk, Novartis, and Sanofi-Aventis; received honoraria as a speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elpen, Galenica, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, Takeda, and Vianex; and attended conferences sponsored by TrigoCare International, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Pfizer, and Sanofi-Aventis. Anca Pantea Stoian is currently Vice President of Romanian National Diabetes Committee, and she has given lectures, received honoraria and research support, and participated in conferences, advisory boards and clinical trials sponsored by many companies including Amgen, AstraZeneca, Boehringer Ingelheim, Medtronic, Eli Lilly, Merck, MSD, Novo Nordisk, Novartis, Roche Diagnostics, Servier, and Sanofi. Ali A. Rizvi has nothing to disclose. Since the completion of this work, A. Rizvi has changed affiliation to the Department of Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA
Andrej Janez discloses consultancies and speaker bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme (MSD), Novo Nordisk, Sanofi, and Medtronic. Manfredi Rizzo is a full-time Professor of Internal Medicine at the University of Palermo, Italy, Editorial Board member of Diabetes Therapy and currently Medical Director in Novo Nordisk Eastern Europe; he has given lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies including Amgen, AstraZeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi, and Servier. None of the aforementioned pharmaceutical companies had any role in this article, which has been written independently, without any financial or professional help, and reflects only the opinion of the authors, without any role of the industry.
No funding or sponsorship was received for this study or publication of this article.
© The Author(s) 2021